Today we announced two research programs through Flagship Pioneering's strategic partnership with Pfizer to identify potential novel targets for the treatment of #cardiovascular and #renal diseases. Under the agreement, our #SomaticGenomics platform will analyze somatic mutations in diseased patient tissue to inform the discovery and development of potentially transformative therapies. Learn more: https://bit.ly/473ta8w
About us
Our Somatic Genomics platform unveils a new universe of genetic variation to create transformational medicines. Learn more at Quotient-Tx.com
- Website
-
https://quotient-tx.com/
External link for Quotient Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held
Employees at Quotient Therapeutics
-
Zeynep Kalender Atak
Principal Scientist, Computational Biology Team Lead at Quotient Therapeutics
-
Janeta Popovici-Muller
Drug Discovery Leader
-
Simon Brunner
Flagship Pioneering | Co-founder at Quotient Therapeutics | Ex-BCG
-
Rui Wang
Immunologist, seasoned biology leader adept in strategic research, team management and project execution
Updates
-
At Quotient, our boundless energy for science fuels creative problem-solving and groundbreaking ideas. Our Head of Data Infrastructure William Spooner says it best: Innovation is at the heart of our culture, guiding us to build the future of #SomaticGenomics. Learn more about what guides our team to success here: https://bit.ly/3WLvOei
-
-
🔬 Our #SomaticGenomics platform offers unparalleled capabilities to identify novel targets, revealing a path to create transformative therapeutics. Discover the future of genetics with our cutting-edge technology: https://bit.ly/3AkWg71
-
-
Are you attending #SXSW2025? Our proposed panel, “The Secret Life of DNA,” will explore advances in technology that allow us to uncover unknown regions of the genome & its potential impact on medicine. Vote for us using SXSW's #PanelPicker through 8/18: https://bit.ly/3AsjGYj
-
-
We're pleased to share that academic co-founder Peter Campbell, Ph.D., who pioneered somatic genomics research while at the Wellcome Sanger Institute, is now joining the Quotient team as chief scientific officer. We look forward to advancing the first ever #SomaticGenomics platform under his leadership. Read more in our press release: https://bit.ly/3YBCkqS
-
-
🎂🧬 Today we celebrate the birthday of Rosalind Franklin, whose groundbreaking X-ray diffraction work was key to discovering #DNA's structure. Her legacy has paved the way for our work in #SomaticGenomics and inspires our innovations every day.
-
-
Companies pioneering original science are key to discovering new medicines. As we explore our #SomaticGenomics platform, we’re proud to be part of the #FlagshipFounded ecosystem of companies, and the many more to come, taking bold scientific leaps for a better future for all.
Flagship Pioneering raises $3.6 billion to fuel critical breakthroughs in human health and sustainability. This expanded capital pool will accelerate the impact of original science and the creation and development of an estimated 25 breakthrough companies in human health, sustainability, and artificial intelligence. Hear from Flagship Founder and CEO Noubar Afeyan about how we're taking #BiggerLeaps by leveraging the power of generative AI, forging novel partnerships with pharma to speed drug development, expanding globally, and promoting and hiring top talent to our leadership ranks. Read the full press release: https://bit.ly/4eQfx05
-
Our academic co-founders contributed to this 2023 study published in Cell Press, highlighting how somatic mutations in liver cells can help to identify adaptive pathways in metabolic liver disease. The research is encouraging as we explore the possibilities of our #SomaticGenomics Platform and human target selection. Read the study here: https://bit.ly/4eCnQfT
-
-
Did you know that natural selection conducts a process akin to a clinical trial at the cellular level to test somatic mutations, allowing Quotient to identify which ones are beneficial vs. neutral vs. disease-causing? Learn how we're leveraging these insights to develop novel medicines that imitate or inhibit a variant's impact: https://bit.ly/3z6OQDW
-
-
This week, we hosted Flagship Pioneering CEO Noubar Afeyan at our UK lab! We're proud to be a part of Flagship's strategic commitment to the UK and look forward to growing Quotient as a vital piece of this biotech community with our #SomaticGenomics platform.
-